South Korea · Delayed Price · Currency is KRW Bio Plus Statistics
Total Valuation
Bio Plus has a market cap or net worth of KRW 323.70 billion. The enterprise value is 376.72 billion.
| Market Cap | 323.70B |
| Enterprise Value | 376.72B |
Important Dates
The last earnings date was Friday, April 3, 2026.
| Earnings Date | Apr 3, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Bio Plus has 61.54 million shares outstanding. The number of shares has increased by 75.73% in one year.
| Current Share Class | 61.54M |
| Shares Outstanding | 61.54M |
| Shares Change (YoY) | +75.73% |
| Shares Change (QoQ) | +237.15% |
| Owned by Insiders (%) | 28.65% |
| Owned by Institutions (%) | 4.88% |
| Float | 43.49M |
Valuation Ratios
The trailing PE ratio is 35.30.
| PE Ratio | 35.30 |
| Forward PE | n/a |
| PS Ratio | 3.56 |
| PB Ratio | 1.66 |
| P/TBV Ratio | 1.95 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 18.34 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.00, with an EV/FCF ratio of -13.02.
| EV / Earnings | 25.11 |
| EV / Sales | 4.14 |
| EV / EBITDA | 20.00 |
| EV / EBIT | 25.50 |
| EV / FCF | -13.02 |
Financial Position
The company has a current ratio of 0.84, with a Debt / Equity ratio of 0.31.
| Current Ratio | 0.84 |
| Quick Ratio | 0.52 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 3.15 |
| Debt / FCF | -2.08 |
| Interest Coverage | 49.36 |
Financial Efficiency
Return on equity (ROE) is 11.51% and return on invested capital (ROIC) is 6.75%.
| Return on Equity (ROE) | 11.51% |
| Return on Assets (ROA) | 3.41% |
| Return on Invested Capital (ROIC) | 6.75% |
| Return on Capital Employed (ROCE) | 7.22% |
| Weighted Average Cost of Capital (WACC) | 5.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.33 |
| Inventory Turnover | 2.37 |
Taxes
| Income Tax | -2.46B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.54% in the last 52 weeks. The beta is 0.47, so Bio Plus's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -20.54% |
| 50-Day Moving Average | 5,186.10 |
| 200-Day Moving Average | 5,995.18 |
| Relative Strength Index (RSI) | 53.82 |
| Average Volume (20 Days) | 231,906 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bio Plus had revenue of KRW 90.90 billion and earned 15.00 billion in profits. Earnings per share was 149.00.
| Revenue | 90.90B |
| Gross Profit | 60.54B |
| Operating Income | 14.99B |
| Pretax Income | 17.54B |
| Net Income | 15.00B |
| EBITDA | 19.05B |
| EBIT | 14.99B |
| Earnings Per Share (EPS) | 149.00 |
Balance Sheet
The company has 27.18 billion in cash and 60.06 billion in debt, with a net cash position of -32.88 billion or -534.26 per share.
| Cash & Cash Equivalents | 27.18B |
| Total Debt | 60.06B |
| Net Cash | -32.88B |
| Net Cash Per Share | -534.26 |
| Equity (Book Value) | 194.98B |
| Book Value Per Share | 2,849.40 |
| Working Capital | -12.52B |
Cash Flow
In the last 12 months, operating cash flow was 17.65 billion and capital expenditures -46.58 billion, giving a free cash flow of -28.93 billion.
| Operating Cash Flow | 17.65B |
| Capital Expenditures | -46.58B |
| Depreciation & Amortization | 4.06B |
| Net Borrowing | 405.52M |
| Free Cash Flow | -28.93B |
| FCF Per Share | -470.05 |
Margins
Gross margin is 66.60%, with operating and profit margins of 16.49% and 16.50%.
| Gross Margin | 66.60% |
| Operating Margin | 16.49% |
| Pretax Margin | 19.29% |
| Profit Margin | 16.50% |
| EBITDA Margin | 20.96% |
| EBIT Margin | 16.49% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.97%.
| Dividend Per Share | 50.00 |
| Dividend Yield | 0.97% |
| Dividend Growth (YoY) | 40.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 19.44% |
| Buyback Yield | -75.73% |
| Shareholder Yield | -74.78% |
| Earnings Yield | 4.63% |
| FCF Yield | -8.94% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 23, 2022. It was a forward split with a ratio of 4.
| Last Split Date | Nov 23, 2022 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
Bio Plus has an Altman Z-Score of 3.54 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.54 |
| Piotroski F-Score | 7 |